Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06192004 · ClinicalTrials.gov registry record
Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy With Risk of Pneumonitis/ILD
A clinical trial, sponsored by AstraZeneca.
- Terminated
- Registry status
- 83
- Enrollment target
NCT06192004 is a clinical trial that was terminated before completion, run by AstraZeneca. The registered enrollment target is 83 participants.
The verdict
NCT06192004 was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- 83 participants
- Enrollment target
Study Summary
This is an observational, prospective, multicenter study conducted in the US to gather evidence in the context of lung cancer to complement the development of a digital solution. Patients initiating treatment for non-small cell lung cancer (NSCLC) will be prospectively followed to characterize risk factors, signs, and symptoms leading to onset, diagnosis, and treatment of pneumonitis/ILD should it occur.
Interventions
- OTHER None (Observational Study)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2024-01-05 |
| Est. Completion | 2025-04-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06192004
The ClinicalTrials.gov registry entry for NCT06192004 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 83 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which None (Observational Study) is the first listed.
NCT06192004 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06192004 about?
NCT06192004 is a clinical study titled "Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy With Risk of Pneumonitis/ILD". This is an observational, prospective, multicenter study conducted in the US to gather evidence in the context of lung cancer to complement the development of a digital solution. Patients initiating treatment for non-small cell lung cancer (NSCLC) will be prospectively followed to characterize risk...
What is the current status of trial NCT06192004?
This trial is currently terminated. The enrollment target is 83 participants. The study started on 2024-01-05. Estimated completion is 2025-04-30.
What interventions are being tested in trial NCT06192004?
The interventions under investigation include: None (Observational Study) (OTHER).
Who is sponsoring clinical trial NCT06192004?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.